Last checked at | Director Dealings Summary - Week Ended April 2 | ||||||||||||
| Company | Name | Position | Number of Shares | Resulting Holding | *Note | GBP Value | ||||||
| BUYS | ||||||||||||
| RM2 International | John Walsh | CEO | 1.2 million | 22.2 million | 648,000 | |||||||
| London Capital Group | Charles-Henri Sabet | CEO | 125,000 | 6.9 million | 340,000 | |||||||
| Hutchison China | Simon To | Chairman | 18,000 | 69,000 | Same day as concept trial for cancer treatment met efficacy target. | 234,000 | ||||||
| Hutchison China | Edith Shih | Non-Executive | 18,000 | 48,000 | Same day as concept trial for cancer treatment met efficacy target. | 234,000 | ||||||
| Standard Life UK Smaller Co's | Allister Langlands | Director | 50,000 | 95,000 | 145,000 | |||||||
| Koovs | Waheed Alli | Chairman | 152,500 | 4.9 million | Same day as Koovs said it would spend more on marketing than anticapted. | 99,000 | ||||||
| Walker Crips | Sean Kin Wai Lam | MD | 221,000 | 422,996 | 95,000 | |||||||
| Walker Crips | Lim Hua Min | Non-Executive | 221,000 | 9.1 million | 95,000 | |||||||
| Monitise | Elizabth Buse | CEO | 500,000 | 1 million | One week after Monitise said it was no longer for sale deciding to remain an independent company. | 66,000 | ||||||
| Stanley Gibbons | Martin Bralsford | Chairman | 22,000 | 204,800 | Same day as profit warning. | 52,000 | ||||||
| Diploma | Andrew Smith | Non-Executive | 5,500 | Undisclosed | 45,000 | |||||||
| Indivior | Shaun Thaxter | CEO | 20,000 | 500,000 | 39,000 | |||||||
| Monitise | Tim Wade | Non-Executive | 250,000 | 350,000 | One week after Monitise said it was no longer for sale deciding to remain an independent company. | 35,000 | ||||||
| 7digital | Donald Cruickshank | Chairman | 140,000 | 290,000 | 24,000 | |||||||
| Synectics | David Coghlan | Chairman | 20,000 | 1.5 million | 23,000 | |||||||
| Plant Impact | John Brubaker | CEO | 40,000 | 646,000 | 21,000 | |||||||
| Mission Marketing | David Morgan | Chairman | 40,000 | 6.1 million | 17,000 | |||||||
| PuriCore | Charles Spicer | Chairman | 50,610 | 75,000 | 16,000 | |||||||
| Inspirit Energy | John Gunn | CEO | 2 million | 355 million | Same day as Inspirit said it will deliver its first micro-combined heat and power boiler to a major utility. | 13,000 | ||||||
| Barclays | John McFarlane | Incoming Chairman | 5,000 | 6,015 | Will become chairman at AGM on April 23. | 12,000 | ||||||
| LPA Goup | Per Staehr | Non-Executive | 15,000 | 185,500 | 11,000 | |||||||
| Progility | Hugh Crawley | CFO | 200,000 | 200,000 | Appointed last Friday. | 11,000 | ||||||
| superGroup | Euan Sutherland | CEO | 10,117 | 11,613 | 9,900 | |||||||
| Lavendon | John Coghlan | Non-Executive | 5,000 | 5,500 | 9600 | |||||||
| Aeorema Communications | Michael Hale | Chairman | 25,000 | 1.7 million | 6,900 | |||||||
| Churchill China | David Taylor | CFO | 1,000 | 21,000 | 6,000 | |||||||
| SOCO International | Anthony Maris | COO | 1,213 | 132,956 | 1,900 | |||||||
| SELLS | ||||||||||||
| Nostrum Oil & Gas | Frank Monstrey | Chairman | 18.7 million | 32.5 million | 2 days after Nostrum reported profit drop. | 109,000,000 | ||||||
| NAHL Group | Samantha Porteous | Non-Executive Director | 3.1 million | Nil | 3 days after NAHL reported profit drop in maiden results. | 7,600,000 | ||||||
| IHG | Tracy Robbins | Director | 28,047 | 183,997 | 738,000 | |||||||
| Michael Page | Oliver Watson | Director | 101,620 | Undisclosed | 540,000 | |||||||
| Jupiter Fund Management | Adrian Creedy | Company Secretary | 100,000 | 1.8 million | 414,000 | |||||||
| STV Group | Rob Woodward | CEO | 100,000 | 419,322 | 383,000 | |||||||
| Nichols | Peter Nichols | Chairman | 17,060 | 2.1 million | 201,000 | |||||||
| Tribal Group | Steve Breach | Finance Director | 81,296 | 172,728 | 2 weeks after Tribal swung to a loss. | 120,000 | ||||||
| Witan Investment Trust | Harry Henderson | Chairman | 2,100 | 722,732 | 17,000 | |||||||
| *Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event. When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director | ||||||||||||
| Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam | ||||||||||||
| Copyright 2015 Alliance News Limited. All Rights Reserved. | ||||||||||||
3 May 2022 11:25
IN BRIEF: US FDA says Hutchmed's pancreatic drug needs more testing
Hutchmed (China) Ltd - Hong Kong-based biopharmaceuticals - The US Food & Drug Administration has rejected Hutchmed's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA says the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively. Chief Executive Officer & Chief Scientific Officer Weiguo Su comments: "Although this decision from the FDA is disappointing, we remain confident about the clinical value of surufatinib for NET patients and committed to making surufatinib available to patients globally. We look forward to working with the agency to evaluate its feedback."
Read more